HC Wainwright & Co. Downgrades Lumos Pharma to Neutral, Lowers Price Target to $4.25
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has downgraded Lumos Pharma from Buy to Neutral and significantly lowered its price target from $28 to $4.25.
October 24, 2024 | 6:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. downgraded Lumos Pharma from Buy to Neutral and reduced the price target from $28 to $4.25, indicating a negative outlook.
The downgrade from Buy to Neutral and the drastic reduction in price target from $28 to $4.25 by a reputable analyst firm suggests a negative outlook for Lumos Pharma, likely leading to a short-term decline in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100